(Q38085684)

28 August 2017

title

Axitinib for the treatment of advanced non-small-cell lung cancer (English)

1 reference

28 August 2017

Siow-Ming Lee

2

0 references

author name string

Judy W King

series ordinal

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

Expert Opinion on Investigational Drugs

28 August 2017

published in

1 reference

28 August 2017

volume

22

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

765-773

1 reference

28 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Current treatments for advanced stage non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

VEGF as a key mediator of angiogenesis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

VEGF-receptor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Angiogenesis-dependent diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Sorafenib for lung cancer: is the "Battle" still open?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Hope and realism: the perfect balance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Axitinib for the management of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.775243

10.1517/13543784.2013.775243

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference